Back to Sectors

MDGL

MADRIGAL PHARMACEUTICALS, INC.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

BEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureBEARISH | 60% | 5/6/2026 | earnings missBULLISH | 90% | 5/6/2026 | margin expansionBULLISH | 70% | 5/6/2026 | acquisitionNEUTRAL | 50% | 5/6/2026 | debt restructureMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%
bearishMay 6

Net loss widened to $94.4 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 6

Maintained exceptionally strong gross margins of approximately 91%.

margin expansion
90%
bullishMay 6

Expanded pipeline via exclusive global licenses for GLP-1, DGAT-2, and siRNA assets.

acquisition
70%
neutralMay 6

Repaid Hercules loan and entered into a new $500 million senior secured credit facility.

debt restructure
50%

Filing History

10-QMay 6, 2026

The Q1 2026 filing presents a classic high-growth biotech trade-off: explosive commercial adoption versus an accelerating burn rate. The surge in Rezdiffra sales proves the market's appetite, but the widening net loss suggests that the cost of acquiring that market share is substantial. The company is currently in a race to achieve operating leverage, where revenue growth must outpace the rising costs of a global commercial organization and an ambitious R&D pipeline. Ultimately, the investment thesis hinges on whether Madrigal can transition from a single-product company to a multi-asset platform without exhausting its capital. The strategic acquisitions of GLP-1 and siRNA assets provide a potential moat, but they also introduce significant milestone obligations and clinical risk. Investors must weigh the impressive 127% revenue growth against the structural risks of high debt and extreme customer concentration.